Next Article in Journal
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Previous Article in Journal
Identification of Potentially Novel Molecular Targets of Endometrial Cancer Using a Non-Biased Proteomic Approach
Previous Article in Special Issue
Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
 
 
Review

Article Versions Notes

Cancers 2023, 15(18), 4669; https://doi.org/10.3390/cancers15184669
Action Date Notes Link
article xml file uploaded 21 September 2023 14:03 CEST Original file -
article xml uploaded. 21 September 2023 14:03 CEST Update https://www.mdpi.com/2072-6694/15/18/4669/xml
article pdf uploaded. 21 September 2023 14:03 CEST Version of Record https://www.mdpi.com/2072-6694/15/18/4669/pdf
article html file updated 21 September 2023 14:05 CEST Original file https://www.mdpi.com/2072-6694/15/18/4669/html
Back to TopTop